Celltrion USA Announces Appointment of Dr. Juby Jacob-Nara, M.D as Senior Vice President and Chief Medical Officer
· Dr. Juby Jacob-Nara brings a wealth of medical and clinical development knowledge and extensive expertise across multiple therapeutic areas and will lead medical strategy at Celltrion USA
JERSEY CITY, N.J., June 2, 2025 – Celltrion USA today announced the appointment of Dr. Juby Jacob-Nara, M.D. as Senior Vice President and Chief Medical Officer. This key leadership appointment reinforces Celltrion’s unwavering patient focus and commitment to expanding access to innovative biologics to improve care for U.S. patients.
“We are delighted to welcome Dr. Jacob-Nara to the Celltrion team,” said Mr. Bon Joong Kim, CEO at Celltrion USA. “Dr. Jacob-Nara’s deep clinical expertise, combined with strong industry experience, will be instrumental to our team and customers as we continue to accelerate the delivery of life-changing therapies to patients and expand our presence in the U.S. market.”
As a dedicated public health physician, Dr. Jacob-Nara brings more than 25 years of experience across sales, marketing, U.S. and global medical affairs, and clinical development across general, specialty, and precision medicines - including biologics, vaccines, and over-the-counter products. Driven by a strong commitment to patient value, she has contributed to the development and expanded access of specialty pharmaceuticals, vaccines, biologics, and direct-to-consumer medicines, with a focus on respiratory, autoimmune, infectious diseases, pain management, and women’s health. She has successfully contributed to more than 50 product launches, including vaccines in the U.S. and globally.
“I am excited to join Celltrion at such a critical and promising time in its growth and evolution,” said Dr. Jacob-Nara. “I look forward to being part of the team, driving transformational change in the pharmaceutical industry and contributing to our shared mission of harnessing scientific innovation to improve outcomes for patients and healthcare professionals across the country.”
Prior to joining Celltrion USA, Dr. Jacob-Nara has held leadership roles at pharmaceutical companies including Merck, Novartis, GSK, AstraZeneca, Pfizer. Most recently serving as Vice President and Head of Global Medical Affairs for Pulmonology, Rhinology & Allergy, Gastroenterology at Sanofi.
Dr. Jacob-Nara holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Kasturba Medical College, a Master of Public Health (MPH) from Columbia University, and a Doctor of Health Science (DHSc) from Radford University. She also earned dual MBAs from Cornell University and Queen’s University.
###
Notes to Editors:
About Celltrion USA
Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on our social media: LinkedIn.
About Celltrion, Inc.
Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipate” the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.
Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
US-25-00059 June 2025